On-Demand Videos

Share

Program Content

Activities

  • EGFR+/High PD-L1 NSCLC
    Treating a Patient With Newly Diagnosed Metastatic EGFR Mutant–Positive NSCLC and High PD-L1 Expression
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 29, 2018

  • PD-L1 for Progressive NSCLC
    PD-L1 Testing in the Setting of Progressive NSCLC After Chemotherapy
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2018

  • PD-L1–Negative Lung Adenocarcinoma
    Treating a Patient With Newly Diagnosed Metastatic Lung Adenocarcinoma and < 1% PD-L1 Expression
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 07, 2018

  • PD-L1–Low Metastatic Squamous NSCLC
    Treating a Patient With Newly Diagnosed Metastatic Squamous NSCLC and Low PD-L1 Expression
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 21, 2018

Faculty

cover img faculity

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

cover img faculity

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

ProCE Banner

Supporters

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology